
Shannon N Westin MD, MPH
Associate Professor, Director, Early Drug Development, Dept. of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TXRecent Contributions to PracticeUpdate:
- Olaparib With or Without Cediranib vs Standard of Care for Recurrent Platinum-Sensitive Ovarian Cancer
- Barriers to Use of PARP Inhibitor Maintenance for Patients With Ovarian Cancer
- Addition of Immunotherapy and PARP Inhibition to Carboplatin Plus Paclitaxel for Advanced Endometrial Cancer
- Microsatellite Instability and Endometrial Cancer
- Key Gynecologic Oncology Presentations at ESMO 2019
- Niraparib Maintenance and Thrombocytopenia for Recurrent Ovarian Cancer
- ESMO: Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer